Real-world outcomes of immunotherapy–based regimens in first-line advanced non-small cell lung cancer

David Waterhouse,Jenny Lam,Keith A Betts,Lei Yin,Sophie Gao,Yong Yuan,John Hartman,Sumati Rao,Solomon Lubinga,David Stenehjem

Lung Cancer（2021）

引用 60|浏览1

暂无评分

摘要

•We assessed real-world survival outcomes for 1L I-O in patients with advanced NSCLC.•Survival estimates were generally lower than those reported in pivotal trials.•There is room for improvement of outcomes in patients who receive 1L I-O regimens.•Specific subgroups may have limited treatment benefit from current I-O therapies.

查看译文

关键词

Non-small cell lung cancer,Real-world outcomes,Immunotherapy,Immune checkpoint inhibitors

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要